Image

The Clinical Efficacy of Immunomodulators in RA Patients

Recruiting
18 - 80 years of age
Both
Phase 4

Powered by AI

Overview

This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.

Description

In this study cohorts, naïve or csDMARDs-IR patients are treated with different csDMARDs combination or TNF inhibitors for 24 weeks to get remission in clinical. The biomarkers in their plasma and synovial fluid and tissue specimens from RA patients are screened to predict the efficacy of specific treatment.

Eligibility

Inclusion Criteria:

-

        1.Patients with RA who meet ACR 1987 rheumatoid arthritis classification criteria or
        ACR/EULAR 2010 rheumatoid arthritis Classification Criteria and have knee dysfunction.
          1. ACR 1987 rheumatoid arthritis classification criteria
               1. morning stiffness lasting at least 1 hour (≥6w)
               2. there are 3 or more joint areas swollen (≥6w)
               3. swelling of the wrist, metacarpophalangeal, and proximal phalangeal joint areas
                  (≥6w)
               4. symmetrical arthrogryposis (≥6w)
               5. hand x-ray changes (at least osteoporosis and joint space narrowing)
               6. positive rheumatoid factor (titer > 1:32) RA can be diagnosed by meeting 4 of the
                  above 7 items
          2. ACR/EULAR 2010 rheumatoid arthritis Classification Criteria
               1. Involved joints
                  - 1 large joint (0 points)
                    -  2-10 large joints (1 point)
                    -  1-3 small joints (with or without large joints) (2 points)
                    -  4-10 small joints (with or without large joints) (3 points)
                    -  more than 10 small joints (at least one small joint) (5 points)
               2. Serological indicators
                    -  RF and ACPA negative (0 points)
                    -  RF and ACPA, at least one of which is low titer positive. (2 points)
                    -  RF and ACPA with at least one high titer positive (3 points)
               3. Acute chronotropic reactants
                    -  Both CRP and ESR normal (0 points)
                    -  Abnormal CRP or ESR (1 point)
               4. Duration of synovitis
                    -  <6 weeks (0 points)
                    -  ≥6 weeks (1 point)
                       2.Patients with OA who meet the 1995 Classification Criteria for OA and have
                       knee dysfunction 1995 Classification Criteria for Osteoarthritis of the Knee
                       Clinical criteria
                       a. Knee pain most of the time in the last 1 month b. Bone rubbing sound c,
                       morning stiffness ≤ 30 minutes d, age ≥ 38 years e, with bony enlargement
                       Knee OA can be diagnosed if a+b+c+d or a+b+e is met
                       3.Age-sex matched healthy volunteers who checked in our hospital.
                       4.Age > 18 years old;
                       5.Voluntarily participate in this study and sign an informed consent form
        Exclusion Criteria:
          1. Patients with combined active hepatitis
          2. Patients with active tuberculosis
          3. Patients withinfection and malignancy

Study details

Arthritis, Rheumatoid

NCT05626348

Qilu Hospital of Shandong University

26 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.